Cervical cancer prevention could become dramatically more accessible worldwide as new evidence demonstrates that a single HPV vaccination provides equivalent protection to the standard two-dose regimen. This finding could revolutionize global immunization strategies, particularly in resource-limited settings where completing multi-dose schedules remains challenging.
A randomized controlled trial involving over 20,000 girls aged 12-16 years found that one dose of either bivalent or nonavalent HPV vaccines prevented high-risk HPV16 and HPV18 infections as effectively as two doses. The study tracked participants for 60 months, measuring persistent infections lasting at least six months. Rate differences between single and double dosing were negligible: -0.13 infections per 100 participants for the bivalent vaccine and 0.21 per 100 for the nonavalent formulation, both well within the predetermined noninferiority threshold.
This represents a potential paradigm shift in cervical cancer prevention strategy. HPV vaccines have demonstrated remarkable efficacy since introduction, yet global uptake remains suboptimal due to logistical barriers, cost constraints, and multi-visit requirements. Single-dose regimens could eliminate follow-up compliance issues that plague current programs, potentially doubling or tripling vaccination coverage in many regions. The implications extend beyond convenience—simplified dosing could accelerate WHO elimination targets for cervical cancer as a public health problem. However, longer-term durability data beyond five years will be crucial, as HPV immunity must persist through peak sexual activity years. While this large, well-designed trial provides compelling evidence, regulatory agencies will likely require additional confirmatory studies before updating official recommendations.